As biopharma’s biologics portfolio continues to grow, its increasing complexity presents a number of challenges for biomanufacturers, according to Sanchayita Ghose, PhD, executive director, Downstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback